{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T05:02:24Z","timestamp":1789794144383,"version":"4.0.1"},"reference-count":105,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BST"],"published-print":{"date-parts":[[2026,8,31]]},"DOI":"10.5582\/bst.2026.01104","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:10:17Z","timestamp":1785449417000},"page":"348-360","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of current global guidelines and consensus on the management of patients with cholangiocarcinoma: A 2026 update"],"prefix":"10.5582","volume":"20","author":[{"given":"Enyang","family":"He","sequence":"first","affiliation":[{"name":"Department of Bile Duct Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China."},{"name":"Research Center for Biliary Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Cai","sequence":"first","affiliation":[{"name":"Department of Bile Duct Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianze","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Bile Duct Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongxing","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Bile Duct Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Bile Duct Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nansheng","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Bile Duct Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China."},{"name":"Research Center for Biliary Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014; 383:2168-2179.","DOI":"10.1016\/S0140-6736(13)61903-0"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Cai Y, Cheng N, Ye H, Li F, Song P, Tang W. The current management of cholangiocarcinoma: A comparison of current guidelines. Biosci Trends. 2016; 10:92-102.","DOI":"10.5582\/bst.2016.01048"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Cardinale V. Classifications and misclassification in cholangiocarcinoma. Liver Internatl. 2019; 39:260-262.","DOI":"10.1111\/liv.13998"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021; 397:428-444.","DOI":"10.1016\/S0140-6736(21)00153-7"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington KM, Carneiro F, Cree IA. The 2019 WHO classification of tumours of the digestive system. Histopathol. 2020; 76:182-188.","DOI":"10.1111\/his.13975"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Zhang X, Cai Y, Xiong X, Liu A, Zhou R, You Z, Li F, Cheng N. Comparison of current guidelines and consensus on the management of patients with cholangiocarcinoma: 2022 update. Intractable &amp; Rare Diseases Res. 2022; 11:161-172.","DOI":"10.5582\/irdr.2022.01109"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Colangelo M, Di Martino M, Polidoro MA, Forti L, Tober N, Gennari A, Pagano N, Donadon M. Management of intrahepatic cholangiocarcinoma: A review for clinicians. Gastroenterol Rep (Oxf). 2025; 13:goaf005.","DOI":"10.1093\/gastro\/goaf005"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Vogel A, Bridgewater J, Edeline J, Kelley RK, Kl\u00fcmpen HJ, Malka D, Primrose JN, Rimassa L, Stenzinger A, Valle JW, Ducreux M. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023; 34:127-140.","DOI":"10.1016\/j.annonc.2022.10.506"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Banales JM, Rodrigues PM, Aff\u00f2 S, <i>et al<\/i>. Cholangiocarcinoma 2026: Status quo, unmet needs and priorities. Nat Rev Gastroenterol Hepatol. 2026; 23:65-96.","DOI":"10.1038\/s41575-025-01153-w"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Benson AB, 3rd, D&apos;Angelica MI, Abrams T, <i>et al<\/i>. Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025; 23:403-418.","DOI":"10.6004\/jnccn.2025.0042"},{"key":"11","unstructured":"11. HPBS-CRHA. Guideline for diagnosis and treatment of perihilar cholangiocarcinoma (2025 edition). Chinese J Hepatic Surg (Electronic Ed). 2025; 24:1-20."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Liu S, Jiang J, Jian Q, <i>et al<\/i>. Chinese multicenter expert consensus on the diagnosis and treatment of hilar cholangiocarcinoma: 2025 edition. Biosci Trends. 2025; 19:379-403.","DOI":"10.5582\/bst.2025.01233"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. EASL Clinical Practice Guidelines on the management of extrahepatic cholangiocarcinoma. J Hepatol. 2025; 83:211-238.","DOI":"10.1016\/j.jhep.2025.03.007"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Vogel A, Ducreux M. ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer. ESMO Open. 2025; 10:104003.","DOI":"10.1016\/j.esmoop.2024.104003"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Macarulla T, Adeva J, Cano Osuna MT, Ruiz Casado A, Jim\u00e9nez Gordo AM, Lamarca A, L\u00f3pez Mu\u00f1oz AM, Pazo Cid RA, Saur\u00ed T, Gallego Plazas J. SEOM-GEMCAD-TTD clinical guidelines for biliary tract cancer (2025). Clin Transl Oncol. 2025; 27:3293-3306.","DOI":"10.1007\/s12094-025-03916-y"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Neuzillet C, Decraecker M, Larrue H, <i>et al<\/i>. Management of intrahepatic and perihilar cholangiocarcinomas: Guidelines of the French Association for the Study of the Liver (AFEF). Liver Internatl. 2024; 44:2517-2537.","DOI":"10.1111\/liv.15948"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kodali S, Kulik L, D&apos;Allessio A, <i>et al<\/i>. The 2024 ILTS-ILCA consensus recommendations for liver transplantation for HCC and intrahepatic cholangiocarcinoma. Liver Transpl. 2025; 31:815-831.","DOI":"10.1097\/LVT.0000000000000589"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Palepu J, Endo I, Chaudhari VA, <i>et al<\/i>. &apos;IHPBA-APHPBA clinical practice guidelines&apos;: International Delphi consensus recommendations for gallbladder cancer. HPB (Oxford). 2024; 26:1311-1326.","DOI":"10.1016\/j.hpb.2024.03.128"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Dar FS, Abbas Z, Ahmed I, <i>et al<\/i>. National guidelines for the diagnosis and treatment of hilar cholangiocarcinoma. World J Gastroenterol. 2024; 30:1018-1042.","DOI":"10.3748\/wjg.v30.i9.1018"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Ramjeesingh R, Chaudhury P, Tam VC, Roberge D, Lim HJ, Knox JJ, Asselah J, Doucette S, Chhiber N, Goodwin R. A practical guide for the systemic treatment of biliary tract cancer in Canada. Curr Oncol. 2023; 30:7132-7150.","DOI":"10.3390\/curroncol30080517"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma. J Hepatol. 2023; 79:181-208.","DOI":"10.1016\/j.jhep.2023.03.010"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Rimassa L, Brandi G, Niger M, Normanno N, Melisi D. Diagnosis and treatment of cholangiocarcinoma in Italy: A Delphi consensus statement. Crit Rev Oncol Hematol. 2023; 192:104146.","DOI":"10.1016\/j.critrevonc.2023.104146"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Rushbrook SM, Kendall TJ, Zen Y, <i>et al<\/i>. British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma. Gut. 2023; 73:16-46.","DOI":"10.1136\/gutjnl-2023-330029"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Nagino M, Hirano S, Yoshitomi H, <i>et al<\/i>. Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition. J Hepatobiliary Pancreat Sci. 2021; 28:26-54.","DOI":"10.1002\/jhbp.870"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Qurashi M, Vithayathil M, Khan SA. Epidemiology of cholangiocarcinoma. Eur J Surg Oncol. 2025; 51:107064.","DOI":"10.1016\/j.ejso.2023.107064"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Florio AA, Ferlay J, Znaor A, Ruggieri D, Alvarez CS, Laversanne M, Bray F, McGlynn KA, Petrick JL. Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012. Cancer. 2020; 126:2666-2678.","DOI":"10.1002\/cncr.32803"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Zou Z, Wang X, Huang B, Shi H, Yin K, Fu T, Han Z. Incidence trends and disparities in infection-related malignancies of the liver among US adults, 2000-2019. Gastroenterol Rep (Oxf). 2025; 13:goaf050.","DOI":"10.1093\/gastro\/goaf050"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Bertuccio P, Malvezzi M, Carioli G, Hashim D, Boffetta P, El-Serag HB, La Vecchia C, Negri E. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019; 71:104-114.","DOI":"10.1016\/j.jhep.2019.03.013"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: Epidemiology and risk factors. Liver Internatl. 2019; 39 Suppl 1:19-31.","DOI":"10.1111\/liv.14095"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatol. 2011; 54:173-184.","DOI":"10.1002\/hep.24351"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Sripa B, Kaewkes S, Sithithaworn P, Mairiang E, Laha T, Smout M, Pairojkul C, Bhudhisawasdi V, Tesana S, Thinkamrop B, Bethony JM, Loukas A, Brindley PJ. Liver fluke induces cholangiocarcinoma. PLoS Med. 2007; 4:e201.","DOI":"10.1371\/journal.pmed.0040201"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Bonadona V, Bona\u00efti B, Olschwang S, <i>et al<\/i>. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011; 305:2304-2310.","DOI":"10.1001\/jama.2011.743"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Okawa Y, Iwasaki Y, Johnson TA, <i>et al<\/i>. Hereditary cancer variants and homologous recombination deficiency in biliary tract cancer. J Hepatol. 2023; 78:333-342.","DOI":"10.1016\/j.jhep.2022.09.025"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Uson Junior PL, Kunze KL, Golafshar MA, <i>et al<\/i>. Germline cancer susceptibility gene testing in unselected patients with hepatobiliary cancers: A multi-center prospective study. Cancer Prev Res (Phila). 2022; 15:121-128.","DOI":"10.1158\/1940-6207.CAPR-21-0189"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Yu H, Xu Y, Gao W, Li M, He J, Deng X, Xing W. Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer. Front Oncol. 2022; 12:930611.","DOI":"10.3389\/fonc.2022.930611"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Lin J, Shi J, Guo H, <i>et al<\/i>. Alterations in DNA Damage Repair Genes in Primary Liver Cancer. Clin Cancer Res. 2019; 25:4701-4711.","DOI":"10.1158\/1078-0432.CCR-19-0127"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Charatcharoenwitthaya P, Enders FB, Halling KC, Lindor KD. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatol. 2008; 48:1106-1117.","DOI":"10.1002\/hep.22441"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol. 2015; 29:221-232.","DOI":"10.1016\/j.bpg.2015.02.003"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Selvaggi F, Lopetuso LR, Delli Pizzi A, Melchiorre E, Murgiano M, Taraschi AL, Cotellese R, Diana M, Vivarelli M, Mocchegiani F, Catalano T, Aceto GM. Diagnosis of cholangiocarcinoma: The new biological and technological horizons. Diagnostics (Basel, Switzerland). 2025; 15.","DOI":"10.3390\/diagnostics15081011"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Han JY, Ahn KS, Kim YH, Kim TS, Baek WK, Suh SI, Kang KJ. Circulating microRNAs as biomarkers in bile-derived exosomes of cholangiocarcinoma. Annals of surgical treatment and research. 2021; 101:140-150.","DOI":"10.4174\/astr.2021.101.3.140"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Hu J, Wang YN, Song DJ, Tan JP, Cao Y, Fan J, Wang Z, Zhou J. A high-accuracy model based on plasma miRNAs diagnoses intrahepatic cholangiocarcinoma: A single center with 1001 samples. Diagnostics (Basel, Switzerland). 2021; 11.","DOI":"10.3390\/diagnostics11040610"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Salem PES, Ghazala RA, El Gendi AM, Emara DM, Ahmed NM. The association between circulating MicroRNA-150 level and cholangiocarcinoma. J Clin Lab Anal. 2020; 34:e23397.","DOI":"10.1002\/jcla.23397"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Arechederra M, Rull\u00e1n M, Amat I, <i>et al<\/i>. Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures. Gut. 2022; 71:1141-1151.","DOI":"10.1136\/gutjnl-2021-325178"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Yoo C, Jeong H, Jeong JH, <i>et al<\/i>. Circulating tumor DNA status and dynamics predict recurrence in patients with resected extrahepatic cholangiocarcinoma. J Hepatol. 2025; 82:861-870.","DOI":"10.1016\/j.jhep.2024.10.043"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Hwang S, Woo S, Kang B, Kang H, Kim JS, Lee SH, Kwon CI, Kyung DS, Kim HP, Kim G, Kim C, Chon HJ. Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer. J Hepatol. 2025; 82:649-657.","DOI":"10.1016\/j.jhep.2024.10.020"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Arbelaiz A, Azkargorta M, Krawczyk M, <i>et al<\/i>. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2017; 66:1125-1143.","DOI":"10.1002\/hep.29291"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Lapitz A, Azkargorta M, Milkiewicz P, <i>et al<\/i>. Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma. J Hepatol. 2023; 79:93-108.","DOI":"10.1016\/j.jhep.2023.02.027"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Cao J, Srinivas-Rao S, Mroueh N, Anand R, Kongboonvijit S, Sertic M, Shenoy-Bhangle AS, Kambadakone A. Cholangiocarcinoma imaging: From diagnosis to response assessment. Abdominal radiology (New York). 2024; 49:1699-1715.","DOI":"10.1007\/s00261-024-04267-y"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Guo HL, Zheng X, Cheng MQ, Zeng D, Huang H, Xie XY, Lu MD, Kuang M, Wang W, Xian MF, Chen LD. Contrast-enhanced ultrasound for differentiation between poorly differentiated hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Ultrasound Med. 2022; 41:1213-1225.","DOI":"10.1002\/jum.15812"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Zhu MR, Zhao CK, Sun YK, Li XL, Yin HH, Lu D, Ye X, Hu XY, Wang X, Xia HS, Han H, Zhou BY, Xu HX, Wang LF. Subtype prediction of intrahepatic cholangiocarcinoma using dynamic contrast-enhanced ultrasound. Insights into imaging. 2024; 15:119.","DOI":"10.1186\/s13244-024-01683-y"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Zerunian M, Polidori T, Palmeri F, Nardacci S, Del Gaudio A, Masci B, Tremamunno G, Polici M, De Santis D, Pucciarelli F, Laghi A, Caruso D. Artificial intelligence and radiomics in cholangiocarcinoma: A comprehensive review. Diagnostics (Basel, Switzerland). 2025; 15.","DOI":"10.3390\/diagnostics15020148"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Wei Y, Yang M, Zhang M, <i>et al<\/i>. Focal liver lesion diagnosis with deep learning and multistage CT imaging. Nature communications. 2024; 15:7040.","DOI":"10.1038\/s41467-024-51260-6"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Njei B, Kanmounye US, Seto N, McCarty TR, Mohan BP, Fozo L, Navaneethan U. Artificial intelligence in medical imaging for cholangiocarcinoma diagnosis: A systematic review with scientometric analysis. J Gastroenterol Hepatol. 2023; 38:874-882.","DOI":"10.1111\/jgh.16180"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Haghbin H, Aziz M. Artificial intelligence and cholangiocarcinoma: Updates and prospects. World J Clin Oncol. 2022; 13:125-134.","DOI":"10.5306\/wjco.v13.i2.125"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Granata V, Fusco R, De Muzio F, <i>et al<\/i>. Risk assessment and cholangiocarcinoma: Diagnostic management and artificial intelligence. Biology. 2023; 12.","DOI":"10.3390\/biology12020213"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Akita M, Fujikura K, Ajiki T, Fukumoto T, Otani K, Azuma T, Itoh T, Ku Y, Zen Y. Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas. Mod Pathol. 2017; 30:986-997.","DOI":"10.1038\/modpathol.2017.22"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Hayashi A, Misumi K, Shibahara J, Arita J, Sakamoto Y, Hasegawa K, Kokudo N, Fukayama M. Distinct Clinicopathologic and genetic features of 2 histologic subtypes of intrahepatic cholangiocarcinoma. Am J Surg Pathol. 2016; 40:1021-1030.","DOI":"10.1097\/PAS.0000000000000670"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Beyersdorf J, Zhang ML. Extrahepatic cholangiocarcinoma: Current concepts in histopathology, immunohistochemistry, and molecular diagnostics. Semin Diagn Pathol. 2025; 42:150949.","DOI":"10.1016\/j.semdp.2025.150949"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. De Santis A, Zhu L, Tao J, Rei\u00dffelder C, Sch\u00f6lch S. Molecular subtypes of intrahepatic cholangiocarcinoma. Trends Mol Med. 2025; 31:755-769.","DOI":"10.1016\/j.molmed.2025.01.008"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Chun YS, Pawlik TM, Vauthey JN. 8th Edition of the AJCC Cancer Staging Manual: Pancreas and Hepatobiliary Cancers. Ann Surg Oncol. 2018; 25:845-847.","DOI":"10.1245\/s10434-017-6025-x"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Lamarca A, Santos-Laso A, Utpatel K, <i>et al<\/i>. Liver metastases of intrahepatic cholangiocarcinoma: Implications for an updated staging system. Hepatology. 2021; 73:2311-2325.","DOI":"10.1002\/hep.31598"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Sa-Ngiamwibool P, Aphivatanasiri C, Sangkhamanon S, <i>et al<\/i>. Modification of the AJCC\/UICC 8th edition staging system for intrahepatic cholangiocarcinoma: Proposal for an alternative staging system from cholangiocarcinoma-prevalent Northeast Thailand. HPB (Oxford). 2022; 24:1944-1956.","DOI":"10.1016\/j.hpb.2022.06.004"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Zhang XF, Xue F, He J, <i>et al<\/i>. Proposed modification of the eighth edition of the AJCC staging system for intrahepatic cholangiocarcinoma. HPB (Oxford). 2021; 23:1456-1466.","DOI":"10.1016\/j.hpb.2021.02.009"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Wu RY, Yang ZM, Feng J, Zhang L, Zhang G. Evaluation and recommendation of the 8th edition of American Joint Committee on Cancer (AJCC) staging system for intrahepatic cholangiocarcinoma (ICC) in 820 patients from the Surveillance, Epidemiology, and End Results (SEER) database. J Gastrointest Surg. 2021; 25:145-154.","DOI":"10.1007\/s11605-020-04557-y"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Wiggers JK, Groot Koerkamp B, Cieslak KP, Doussot A, van Klaveren D, Allen PJ, Besselink MG, Busch OR, D&apos;Angelica MI, DeMatteo RP, Gouma DJ, Kingham TP, van Gulik TM, Jarnagin WR. Postoperative mortality after liver resection for perihilar cholangiocarcinoma: Development of a risk score and importance of biliary drainage of the future liver remnant. J Am Coll Surg. 2016; 223:321-331.e321.","DOI":"10.1016\/j.jamcollsurg.2016.03.035"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Anteby R, Vierra BM, Shah SA. Liver transplant for intrahepatic cholangiocarcinoma: Current evidence and clinical practice recommendations. J Gastrointest Surg. 2025; 29:102211.","DOI":"10.1016\/j.gassur.2025.102211"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Munir MM, Ruff SM, Endo Y, Lima HA, Alaimo L, Moazzam Z, Shaikh C, Pawlik TM. Does adjuvant therapy benefit low-risk resectable cholangiocarcinoma? An evaluation of the NCCN Guidelines. J Gastrointest Surg. 2023; 27:511-520.","DOI":"10.1007\/s11605-022-05558-9"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Rhodin KE, Liu A, Bartholomew A, <i>et al<\/i>. Trends in receipt of adjuvant chemotherapy and its impact on survival in resected biliary tract cancers. Ann Surg Oncol. 2023; 30:4813-4821.","DOI":"10.1245\/s10434-023-13567-4"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Xu R, Zhou J, Yang J, Yu Y, Wang H, Zhang Z, Yang J, Zhang G, Liao R. First-line systemic therapy and sequencing options in advanced biliary tract cancer: A systematic review and network meta-analysis. Biosci Trends. 2025; 18:555-562.","DOI":"10.5582\/bst.2024.01376"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Mosconi C, Solaini L, Vara G, Brandi N, Cappelli A, Modestino F, Cucchetti A, Golfieri R. Transarterial chemoembolization and radioembolization for unresectable intrahepatic cholangiocarcinoma-A systemic review and meta-analysis. Cardiovasc Intervent Radiol. 2021; 44:728-738.","DOI":"10.1007\/s00270-021-02800-w"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. Blair AB, Alobuia WM, Palta M, Raman SS, Levine MH, Benson AB, 3rd, D&apos;Angelica MI, Cloyd JM. Locoregional treatment options for locally advanced intrahepatic cholangiocarcinoma. J Natl Compr Canc Netw. 2025; 23.","DOI":"10.6004\/jnccn.2025.7085"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72. Zhang W, Zhou H, Wang Y, Zhang Z, Cao G, Song T, Zhang T, Li Q. Systemic treatment of advanced or recurrent biliary tract cancer. Biosci Trends. 2020; 14:328-341.","DOI":"10.5582\/bst.2020.03240"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Zhang D, Dorman K, Westphalen CB, Haas M, Ormanns S, Neumann J, Seidensticker M, Ricke J, De Toni EN, Klauschen F, Alg\u00fcl H, Reisl\u00e4nder T, Boeck S, Heinemann V. Unresectable biliary tract cancer: Current and future systemic therapy. Eur J Cancer. 2024; 203:114046.","DOI":"10.1016\/j.ejca.2024.114046"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74. Ilyas SI, Affo S, Goyal L, Lamarca A, Sapisochin G, Yang JD, Gores GJ. Cholangiocarcinoma - Novel biological insights and therapeutic strategies. Nat Rev Clin Oncol. 2023; 20:470-486.","DOI":"10.1038\/s41571-023-00770-1"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75. Loeuillard E, Yang J, Buckarma E, Wang J, Liu Y, Conboy C, Pavelko KD, Li Y, O&apos;Brien D, Wang C, Graham RP, Smoot RL, Dong H, Ilyas S. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma. J Clin Invest. 2020; 130:5380-5396.","DOI":"10.1172\/JCI137110"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76. Fabris L, Sato K, Alpini G, Strazzabosco M. The tumor microenvironment in cholangiocarcinoma progression. Hepatology. 2021; 73 Suppl 1:75-85.","DOI":"10.1002\/hep.31410"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77. Liu J, Shu J. Immunotherapy and targeted therapy for cholangiocarcinoma: Artificial intelligence research in imaging. Crit Rev Oncol Hematol. 2024; 194:104235.","DOI":"10.1016\/j.critrevonc.2023.104235"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78. Mosele MF, Westphalen CB, Stenzinger A, <i>et al<\/i>. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: A report from the ESMO Precision Medicine Working Group. Ann Oncol. 2024; 35:588-606.","DOI":"10.1016\/j.annonc.2024.04.005"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79. Goyal L, Meric-Bernstam F, Hollebecque A, <i>et al<\/i>. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023; 388:228-239.","DOI":"10.1056\/NEJMoa2206834"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80. Harding JJ, Fan J, Oh DY, <i>et al<\/i>. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): A multicentre, single-arm, phase 2b study. Lancet Oncol. 2023; 24:772-782.","DOI":"10.1016\/S1470-2045(23)00242-5"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81. Harding JJ, Piha-Paul SA, Shah RH, <i>et al<\/i>. Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers. Nature Communications. 2023; 14:630.","DOI":"10.1038\/s41467-023-36399-y"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82. Subbiah V, Kreitman RJ, Wainberg ZA, <i>et al<\/i>. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: The phase 2 ROAR trial. Nat Med. 2023; 29:1103-1112.","DOI":"10.1038\/s41591-023-02321-8"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83. Javle M, Roychowdhury S, Kelley RK, <i>et al<\/i>. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: Mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021; 6:803-815.","DOI":"10.1016\/S2468-1253(21)00196-5"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84. Ten Haaft BH, Pedregal M, Prato J, Kl\u00fcmpen HJ, Moreno V, Lamarca A. Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives. Eur J Cancer. 2024; 199:113564.","DOI":"10.1016\/j.ejca.2024.113564"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85. Ellis H, Braconi C, Valle JW, Bardeesy N. Cholangiocarcinoma targeted therapies: Mechanisms of action and resistance. Am J Pathol. 2025; 195:437-452.","DOI":"10.1016\/j.ajpath.2024.11.005"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86. Buettner S, Groot Koerkamp B. The Japanese Clinical Practice Guidelines for intrahepatic cholangiocarcinoma: A comparison with Western guidelines. Hepatobiliary surgery and nutrition. 2023; 12:244-247.","DOI":"10.21037\/hbsn-23-30"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87. Wheless M, Agarwal R, Goff L, Lockney N, Padmanabhan C, Heumann T. Current standards, multidisciplinary approaches, and future directions in the management of extrahepatic cholangiocarcinoma. Curr Treat Options Oncol. 2024; 25:127-160.","DOI":"10.1007\/s11864-023-01153-5"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88. Songserm N, Namwong W, Woradet S, Sripa B, Ali A. Public health interventions for preventing re-infection of Opisthorchis viverrini: Application of the self-efficacy theory and group process in high-prevalent areas of Thailand. Trop Med Int Health. 2021; 26:962-972.","DOI":"10.1111\/tmi.13598"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89. Laithavewat L, Grundy-Warr C, Khuntikeo N, Andrews RH, Petney TN, Yongvanit P, Banchonhattakit P, Sithithaworn P. Analysis of a school-based health education model to prevent opisthorchiasis and cholangiocarcinoma in primary school children in northeast Thailand. Global Health Promotion. 2020; 27:15-23.","DOI":"10.1177\/1757975918767622"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90. Ouyang G, Liu Q, Wu Y, Liu Z, Lu W, Li S, Pan G, Chen X. The global, regional, and national burden of gallbladder and biliary tract cancer and its attributable risk factors in 195 countries and territories, 1990 to 2017: A systematic analysis for the Global Burden of Disease Study 2017. Cancer. 2021; 127:2238-2250.","DOI":"10.1002\/cncr.33476"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91. Chen S, Han K, Song Y, Liu S, Li X, Wang S, Li H, Li R, Wang J, He Y, Liu M. Current status, trends, and predictions in the burden of gallbladder and biliary tract cancer in China from 1990 to 2019. Chin Med J (Engl). 2022; 135:1697-1706.","DOI":"10.1097\/CM9.0000000000002258"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92. Bridgewater J, Fletcher P, Palmer DH, <i>et al<\/i>. Long-term outcomes and exploratory analyses of the randomized phase III BILCAP study. J Clin Oncol. 2022; 40:2048-2057.","DOI":"10.1200\/JCO.21.02568"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93. Oh DY, He AR, Bouattour M, <i>et al<\/i>. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): Updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024; 9:694-704.","DOI":"10.1016\/S2468-1253(24)00095-5"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94. Kelley RK, Ueno M, Yoo C, <i>et al<\/i>. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023; 401:1853-1865.","DOI":"10.1016\/S0140-6736(23)00727-4"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95. Lamarca A, Palmer DH, Wasan HS, <i>et al<\/i>. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): A phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021; 22:690-701.","DOI":"10.1016\/S1470-2045(21)00027-9"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96. Zhu AX, Macarulla T, Javle MM, <i>et al<\/i>. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 Mutation: The phase 3 randomized clinical ClarIDHy trial. JAMA oncology. 2021; 7:1669-1677.","DOI":"10.1001\/jamaoncol.2021.3836"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97. Subbiah V, Lassen U, \u00c9lez E, <i>et al<\/i>. Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): A phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020; 21:1234-1243.","DOI":"10.1016\/S1470-2045(20)30321-1"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98. Li Z, Aliseda D, Jones O, Rajendran L, Magyar C, Grant R, O&apos;Kane GM, Saborowski A, Sapisochin G, Vogel A. Recent advances in systemic therapy for advanced biliary tract cancer: A systematic review and meta-analysis using reconstructed RCT survival data. JHEP reports : innovation in hepatology. 2025; 7:101290.","DOI":"10.1016\/j.jhepr.2024.101290"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99. Vedeld HM, Grimsrud MM, Andresen K, <i>et al<\/i>. Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile. Hepatology. 2022; 75:59-73.","DOI":"10.1002\/hep.32125"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100. Cleary JM, Raghavan S, Wu Q, <i>et al<\/i>. FGFR2 extracellular domain in-frame deletions are therapeutically targetable genomic alterations that function as oncogenic drivers in cholangiocarcinoma. Cancer Discov. 2021; 11:2488-2505.","DOI":"10.1158\/2159-8290.CD-20-1669"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101. Meric-Bernstam F, Bahleda R, Hierro C, Sanson M, Bridgewater J, Arkenau HT, Tran B, Kelley RK, Park JO, Javle M, He Y, Benhadji KA, Goyal L. Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: A phase I dose-expansion study. Cancer Discov. 2022; 12:402-415.","DOI":"10.1158\/2159-8290.CD-21-0697"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102. Verdaguer H, Saur\u00ed T, Acosta DA, <i>et al<\/i>. ESMO scale for clinical actionability of molecular targets driving targeted treatment in patients with cholangiocarcinoma. Clin Cancer Res. 2022; 28:1662-1671.","DOI":"10.1158\/1078-0432.CCR-21-2384"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103. Bekaii-Saab TS, Bridgewater J, Normanno N. Practical considerations in screening for genetic alterations in cholangiocarcinoma. Ann Oncol. 2021; 32:1111-1126.","DOI":"10.1016\/j.annonc.2021.04.012"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104. Ruff SM, Cloyd JM, Pawlik TM. Annals of Surgical Oncology Practice Guidelines Series: Management of primary liver and biliary tract cancers. Ann Surg Oncol. 2023; 30:7935-7949.","DOI":"10.1245\/s10434-023-14255-z"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105. Ji GW, Xu ZG, Liu SC, Cao SY, Jiao CY, Lu M, Zhang B, Yang Y, Xu Q, Wu XF, Wang K, Xia YX, Li XC, Wang XH. Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target. Clinical Molec Hepatol. 2025; 31:935-959.","DOI":"10.3350\/cmh.2024.0895"}],"container-title":["BioScience Trends"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/20\/4\/20_2026.01104\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:29:51Z","timestamp":1789792191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/20\/4\/20_2026.01104\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":105,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5582\/bst.2026.01104","relation":{},"ISSN":["1881-7815","1881-7823"],"issn-type":[{"value":"1881-7815","type":"print"},{"value":"1881-7823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"2026.01104"}}